U.S. drug regulators have directed health care workers in eight states to stop using a COVID-19 treatment because it may not be effective against an Omicron subvariant that is rising in prevalence. The Food and Drug Administration (FDA) said sotrovimab, a monoclonal antibody used to treat COVID-19, can no longer be used in Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Rhode Island, and Vermont. Providers in Puerto Rico and the Virgin Islands are also being told to stop using stotrovimab. Regulators believe the treatment, which was given emergency use authorization in May 2021, “is unlikely to be effective against the BA.2 subvariant,” the FDA said in a statement. BA.2 is a subvariant of Omicron, a variant of the CCP (Chinese Communist Party) virus. According to genomic surveillance conducted by the Centers for Disease Control and Prevention, BA.2 was responsible for 12.6 percent of COVID-19 cases in the United States …